What question did this study set out to answer?

To compare the effectiveness of orforglipron and oral semaglutide in reducing HbA1c in patients with inadequately controlled type 2 diabetes on metformin.

June 4, 2026Annals of Internal Medicine0 citations

View Full Paper

In T2D inadequately controlled with metformin, orforglipron reduced HbA 1c more than oral semaglutide at 52 wk

DLDarren Lau

Key Result

Orforglipron reduced HbA1c more than oral semaglutide at 52 weeks in patients with type 2 diabetes inadequately controlled with metformin.

Key Points

To compare the effectiveness of orforglipron and oral semaglutide in reducing HbA1c in patients with inadequately controlled type 2 diabetes on metformin.
Randomized trial
Patients inadequately controlled on metformin
Intervention with orforglipron and oral semaglutide for 52 weeks.
Orforglipron significantly reduced HbA1c compared to semaglutide by week 52, with a notable percent decrease unspecified in the abstract.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

CLINICAL IMPACT RATINGS: GIM/FP/GP: Formula: see text Endocrinology: Formula: see text.

Ask AI

Helpful

Bookmark

View Full Paper

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Darren Lau (Mon,) reported a other. Orforglipron reduced HbA1c more than oral semaglutide at 52 weeks in patients with type 2 diabetes inadequately controlled with metformin.

synapsesocial.com/papers/6a211549d499ed480b16e765 https://doi.org/https://doi.org/10.7326/annals-26-01781-jc